Search
clobazam (ONFI, Frisium, Urbanol)
Indications:
- adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients >= 2 years of age
Dosage: oral
Tabs: 5, 10, & 20 mg
Pharmacokinetics:
- elimination 1/2 life of 18 hours
Adverse effects:
- sedation, dizziness, constipation [5]
- tolerance, pyrexia
- Stevens-Johnson syndrome (SJS) [5]
- toxic epidermal necrolysis (TEN) [4] (rare)
- benzodiazepine withdrawal [5]
Mechanism of action:
- thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA-A receptor
Interactions
drug adverse effects of benzodiazepines
General
benzodiazepine
References
- Business Wire: Oct 24, 2011
FDA Approves ONFI (clobazam) for the Adjunctive Treatment
of Seizures Associated with Lennox-Gastaut Syndrome in Patients
Two Years and Older
http://www.businesswire.com/news/home/20111024005933/en/FDA-Approves-ONFI%E2%84%A2-clobazam-Adjunctive-Treatment-Seizures
- Wikipedia: Clobazam
http://en.wikipedia.org/wiki/Clobazam
- Hanks GW
Clobazam: Pharmacological and therpeutic profile
Br J Clin Pharmacol. 1979; 7(Suppl 1): 151S-155S
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429523/
- FDA Drug Safety Communication: 12-3-2013
FDA warns of serious skin reactions with the anti-seizure drug
Onfi (clobazam) and has approved label changes.
http://www.fda.gov/Drugs/DrugSafety/ucm377204.htm
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015